Caribou Biosciences, Inc. (CRBU)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Caribou Biosciences, Inc. (CRBU)
Company Performance

Current Price

as of Oct 16, 2024

$2.06

P/E Ratio

N/A

Market Cap

$186.15M

Description

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Metrics

Overview

  • HQBerkeley, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerCRBU
  • Price$2.06+5.64%

Trading Information

  • Market Cap$186.15M
  • Float88.33%
  • Average Daily Volume (1m)823,240
  • Average Daily Volume (3m)1,002,300
  • EPS-$1.39

Company

  • Revenue$33.11M
  • Rev Growth (1yr)-7.75%
  • Net Income-$37.70M
  • Gross Margin75.29%
  • EBITDA Margin-1,231.09%
  • EBITDA-$42.65M
  • EV-$86.16M
  • EV/Revenue-2.60
  • P/EN/A
  • P/S5.62
  • P/B0.60
Documents
SEC Filings
8-K (2024-09-03)
8-K (2024-08-12)
8-K (2024-08-06)
8-K (2024-07-16)
8-K (2024-06-14)
8-K (2024-06-03)
8-K (2024-05-07)
8-K (2024-04-04)
8-K (2024-03-11)
8-K (2024-01-08)
8-K (2023-12-22)
8-K (2023-12-12)
8-K (2023-11-07)
8-K (2023-10-18)
8-K (2023-09-26)
8-K (2023-08-08)
8-K (2023-07-17)
8-K (2023-07-13)
8-K (2023-07-06)
8-K (2023-06-16)
8-K (2023-05-09)
8-K (2023-04-04)
8-K (2023-03-29)
8-K (2023-03-24)
8-K (2023-03-09)
10-Q (2024-08-06)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-09)
10-K (2024-03-11)
10-K (2023-03-09)
Wikipedia
Caribou_Biosciences
Factset Street Account
FDA grants orphan drug designation to Caribou Biosciences for drug to treat multiple myeloma ($5.46, +0.16) (2023-11-22T17:53:58Z)
Caribou Biosciences reports Q3 EPS ($0.12) vs FactSet ($0.42) [6 est, ($0.53)-(0.28)] ($4.76, 0.00) (2023-11-07T21:04:46Z)
Caribou Biosciences initiated neutral at Cantor Fitzgerald ($4.77, 0.00) (2023-11-08T11:36:07Z)
Caribou Biosciences announces FDA clearance of IND application for CB-012 allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia ($4.33, 0.00) (2023-10-18T12:03:14Z)
Factset
Factset Business Description